Correlation of Hematologic Coefficients of Inflammation and Metabolic Syndrome: Pilot Study
https://doi.org/10.52667/2712-9179-2025-5-2-31-36
Abstract
Antipsychotic therapy often causes side effects, one of which is metabolic syndrome. This condition increases the risk of cardiovascular disease and increases mortality in patients with schizophrenia. Currently, to improve the safety of antipsychotic therapy, the possibility of introducing into clinical practice the monitoring of hematologic inflammation coefficients as predictors of the development of metabolic syndrome is being considered. Objective: was to determine the presence of correlation between hematologic inflammation coefficients and metabolic syndrome in patients with schizophrenia. Methods: The study included 32 patients diagnosed with schizophrenia paranoid (F20.0, ICD-10), treated in a psychiatric hospital and receiving clozapine therapy. Patients were divided into two groups according to the presence or absence of metabolic syndrome. Metabolic syndrome was defined according to the International Diabetes Federation criteria. The groups were matched as similar as possible in terms of sex, age, therapy, smoking status and comorbidities of the patients. Results: In our study, no significant differences were found between patients with absence and presence of metabolic syndrome in terms of hematologic inflammation coefficients: neutrophil to lymphocyte ratio (p=0.752), monocyte to lymphocyte ratio (p = 0.734), systemic immune inflammation index (SII) (p=0.564), monocyte to high density lipoprotein ratio (p = 0.169). Discussion. The results of our study showed no significant differences between schizophrenic patients with metabolic syndrome and those without metabolic syndrome in terms of hematologic inflammatory coefficients. This may suggest that these inflammatory markers are not reliable predictors of the development of metabolic syndrome in patients with schizophrenia receiving clozapine therapy. Conclusion. However, these findings require further investigation, as existing data on the relationship between inflammatory processes and metabolic disorders in patients with psychiatric disorders remain inconsistent.
Supporting agencies: The study was performed within the framework of the state assignment of the ”Bekhterev’s National Medical Research Center For Psychiatry and Neurology of the Ministry of Health of Russia” (XSOZ 2024 0012). The authors are grateful to the administration and management of the V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology and also thank the Director of the Centre, Scientific Head of the Geriatric Psychiatry Department of the Centre, Doctor of Medical Sciences, Professor N. G. Neznanov for the opportunity to conduct this project.
About the Authors
Alla V. Kidyaeva
V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology
Russian Federation
Russian Federation
192019 Saint Petersburg.
Anastasiya V. Eichelberg
V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology
Russian Federation
Russian Federation
192019 Saint Petersburg.
Natalia A. Shnayder
V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology
Russian Federation
Russian Federation
192019 Saint Petersburg.
Regina F. Nasyrova
V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology
Russian Federation
Russian Federation
192019 Saint Petersburg.
References
1. Drug-induced long QT syndrome in psychiatry and neurology. Edited by R. F. Nasyrova, N. G. Neznanov, N. A. Schneider, M. M. Petrova. St. Petersburg: DEAN Publishing House; 2024. (In Russ.). ISBN 978-5-6051473-9-8
2. Kidyaeva, A.V.; Nasyrova, R.F. The role of cariprazine in the prevention and correction of antipsychotic-induced cardiometabolic disorders. Sovrem. ter. psih. rasstrojstv [Сurrent Therapy of Mental Disorders]. 2024, 3:51-57. doi: 10.21265/PSYPH.2024.75.87.005
3. Nasyrova, R.F.; Kidyaeva, A.V.; Petrova, M.M.; Shnayder, N.A. Antipsychotic-induced QT prolongation and torsade de pointes in patients with mental disorders: A review. Safety and Risk of Pharmacotherapy. 2024, 12(4):380-395. (In Russ.) doi: 10.30895/2312-7821-2024-410
4. Kaar, S.J.; Natesan, S.; McCutcheon, R.; Howes, O.D. Antipsychotics: Mechanisms underlying clinical responseand side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. 2020, 172:107704. doi: 10.1016/j.neuropharm.2019.107704
5. Mahmood, A.; Haider, H.; Samad, S.; Kumar, D.; Perwaiz, A.; Mushtaq, R.; Ali, A.; Farooq, M.Z.; Farhat, H. Association of white blood cell parameters with metabolic syndrome: A systematic review and meta-analysis of 168,000 patients. Medicine (Baltimore). 2024; 103(10):e37331. doi: 10.1097/MD.0000000000037331
6. Zhang, S.S.; Yang, X.J.; Ma, Q.H.; Xu, Y.; Chen, X.; Wang, P.; Pan, C.W. Leukocyte related parameters in olderadults with metabolically healthy and unhealthy over weight or obesity. SciRep. 2021, 11(1):4652. doi: 10.1038/s41598-021-84367-7.
7. Kibitov A.O.; Shumskaya D.S. Modern genome-wide association studies of mental disorders: focus on the mechanisms of inflammation. Siberian Herald of Psychiatry and Addiction Psychiatry. 2024, 4 (125): 56-65. doi: 10.26617/1810-3111-2024-4(125)-56-65.
8. Varun, C.N.; Venkataswamy, M.M.; Ravikumar, R.; Nagaraju, R.; Debnath, M.; Varambally, S.; Venkatasubramanian, G.; Ravi, V. Th17 and MAIT cell mediated inflammation in antipsychotic free schizophrenia patients. SchizophrRes. 2019, 212:47-53. doi: 10.1016/j.schres.2019.08.013
9. Adali M. K.; Buber I.; Kilic O.; Turkoz A.; Yilmaz S. Ticagrelor improves systemic immune-inflammation index in acute coronary syndrome patients. Acta Cardiol. 2022, 77(7):632–638 doi: 10.1080/00015385.2021.1973770
10. Bustan Y.; Drapisz A.; Dor DHB, Avrahami M.; Schwartz-Lifshitz M.; Weizman A.; Barzilay R: Elevated neutrophil to lymphocyte ratioin non-affective psychotic adolescent inpatients: Evidence for early association between inflammation and psychosis. Psychiatry research. 2018, 262:149-153 doi: 10.1016/j.psychres.2018.02.002
11. Ivković M; Pantović-Stefanović M.; Dunjić-Kostić B.; Jurišić, V; Lačković, M; Totić-Poznanović, S; Jovanović, A.A.; Damjanović. A. Neutrophil-to-lymphocyte ratio predicting suicide risk in euthymic patients with bipolar disorder: Moderatory effect of family history. ComprPsychiatry. 2016, 66:87–95. doi: 10.1016/j.comppsych.2016.01.005
12. Karageorgiou, V.; Milas, G.P.; Michopoulos, I. Neutrophil-to-lymphocyte ratio in schizophrenia: A systematicreview and meta-analysis. SchizophrRes. 2019; 206:4-12. doi: 10.1016/j.schres.2018.12.017
13. Geneva, I. (1993). ICD-10. Classification of Mental and Behavioral Disorders-2010.
14. Nasyrova R.F.; KidyaevaA.V.; GrechkinaV.V.; PetrovaM.M.; ShnayderN.A.; Personalized Approach to Predictionand Prevention Clozapine-Induced QT Prolongation. Psychiatry (Moscow) (Psikhiatriya). 2024; 22(5):73–84. (In Russ.). doi: 10.30629/2618-6667-2024-22-5-73-84
15. Zhu, X.; Zhou, J.; Zhu, Y.; Yan, F.; Han, X.; Tan, Y.; Li, R. Neutrophil/lymphocyte, platelet/lymphocyte and monocyte/lymphocyte ratios in schizophrenia. Australas Psychiatry. 2022; 30(1):95-99. doi: 10.1177/10398562211022753
16. ZakharovaN.V.; NasyrovaR.F.; RakhmatullinA.I.; RumiantcevaM.N.; SizykhK.I.; KostinF.N. Neutrophil-to-Lymphocyte Ratio Any Association with Metabolic Syndromein Schizophrenia. Personalized Psychiatry and Neurology. 2024; 4(3):12-23. doi: 10.52667/2712-9179-2024-4-3-12-23
17. Zakharova N.V., Kidyaeva A.V., Grechkina V.V., Boyko I.R., Rakhmatullin A.I., Tabak M.V., Nasyrova R.F. Neutrophil-to-lymphocyte ratio any association with metabolic syndrome in schizophrenia, Systematic review. Personalized Psychiatry and Neurology. 2025; 5(1):27-31. doi: 10.52667/2712-9179-2025-5-1-27-31
18. Nasyrova R.F.; Kidyaeva A.V.; Shnayder N.A. Hematological Predictors of Antipsychotic-induced Metabolic Syndromein a Female Patient with Schizophrenia: CaseReport. Personalized Psychiatry and Neurology. 2024; 4(2):39-46. doi: 10.52667/2712-9179-2024-4-2-39-46
19. Gorbunova, A.P.; Rukavishnikov, G.V.; Kasyanov, E.D.; Mazo, G.E. The role of hematological coefficients of systemic inflammation in the diagnosis and risk assessment of affective disorders. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2024; 58(1):47-55. doi: 10.31363/2313-7053-2024-794
20. Popov M.; Popov Y.; Kosterin D.; Lepik O. Inflammatory Hematological Ratios in Adolescents with Mental Disorders: A Scoping Review Consortium Psychiatricum. 2024. Vol. 5. - N. 2. - P. 45-61. doi: 10.17816/CP15514
21. Emelina D A.; Kravchenko I.V.; Makarov I.V.; Gasanov R.F.; Prokhorenko Ekaterina S. The Role of Systemic Inflammation in Psychiatric Disorders Development in Children: Literature Review. Voprosy sovremennoi pediatrii — Current Pediatrics. 2024; 23(4):204–212. (In Russ). doi: 10.15690/vsp.v23i4.2780
22. Sanchez-Autet, M.; Arranz, B.; Sierra, P.; Safont, G.; Garcia-Blanco, A.; de la Fuente, L.; Garriga, M.; Marín, L.; García-Portilla, M.P. Association between neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and C-reactive protein levels and metabolic status in patients with a bipolar disorder. World J. Biol. Psychiatry. 2022, 6:464–474. doi: 10.1080/15622975.2021.2013089
23. Prestwood, T.R.; Asgariroozbehani, R.; Wu, S.; Agarwal, S.M.; Logan, R.W.; Ballon, J.S.; Hahn, M.K.; Freyberg, Z. Roles of inflammation in intrinsic pathophysiology and antipsychoticdrug-induced metabolic disturbances of schizophrenia. BehavBrainRes. 2021; 402:113101. doi: 10.1016/j.bbr.2020.113101
24. Cordova, V.H.S.; Teixeira, A.D.; Anzolin, A.P.; Moschetta, R.; Belmonte-de-Abreu, P.S. Inflammatory markers in out patients with schizophrenia diagnosisin regularuse of clozapine: a cross-sectionalstudy. FrontPsychiatry. 2023; 14:1269322. doi: 10.3389/fpsyt.2023.1269322
25. Seeman, M.V. The Pharmacodynamics of Antipsychotic Drugsin Womenand Men. Front Psychiatry. 2021; 12:650904. doi: 10.3389/fpsyt.2021.650904
Review
For citations:
Kidyaeva A.V., Eichelberg A.V., Shnayder N.A., Nasyrova R.F. Correlation of Hematologic Coefficients of Inflammation and Metabolic Syndrome: Pilot Study. Personalized Psychiatry and Neurology. 2025;5(2):31-36. https://doi.org/10.52667/2712-9179-2025-5-2-31-36
Views:
48
Email this article 